Posted in General 
July 22nd, 2009

Novavax Inc. (Nasdaq: NVAX) shares are up 2.5 percent to $3.27 on premarket volume of about 180,000 shares just after 9 a.m. Eastern. The company said it has selected a respiratory virus candidate for additional preclinical studies to support an investigational new drug application. The company says the selected vaccine has been shown to protect mice against RSV disease and can be produced at commercial manufacturing yields. — Mike Tarsala

Comments are closed